XTNT Xtant Medical Holdings, Inc.
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1453593 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-24.4%
TTM net income YoY-1,014.2%
TTM EPS YoY-1,200.0%
Revenue 3-yr CAGR8.6%
Net income 3-yr CAGR—
Margins
Gross margin56.4%
Operating margin-16.0%
Net margin-15.9%
FCF margin-6.1%
EBITDA margin-12.6%
Returns
ROE-36.5%
ROA-17.6%
ROIC (approx.)-26.2%
Asset turnover1.11x
Leverage & solvency
Liabilities / assets50.5%
Debt / equity0.27x
Current ratio2.00x
Interest coverage-6.56x
Cash quality & payout
Operating cash flow / net income0.31x
Accruals ratio-12.2%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $24.29M | $23.03M | $20.88M | $32.36M | $33.26M | $35.41M | $32.90M | $31.51M |
| Cost of revenue | $10.62M | $9.70M | $8.91M | $14.60M | $11.26M | $11.13M | $12.66M | $15.49M |
| Gross profit | $13.66M | $13.33M | $11.97M | $17.75M | $21.99M | $24.28M | $20.24M | $16.02M |
| R&D expense | $496,000 | $695,000 | $435,000 | $459,000 | $634,000 | $566,000 | $443,000 | $522,000 |
| SG&A expense | $5.01M | $6.44M | $6.27M | $7.29M | $7.07M | $7.48M | $7.53M | $5.70M |
| Operating income | -$3.03M | -$9.17M | -$2.92M | -$944,000 | $2.54M | $4.62M | $1.06M | -$1.88M |
| Interest expense | $590,000 | $542,000 | $599,000 | $718,000 | $904,000 | $1.00M | $1.04M | $1.13M |
| Pretax income | -$3.40M | -$9.34M | -$3.06M | $1.60M | $1.56M | $3.81M | $33,000 | -$3.14M |
| Income tax | $165,000 | $73,000 | $27,000 | $1.54M | $257,000 | $255,000 | -$25,000 | $21,000 |
| Net income | -$3.56M | -$9.41M | -$3.09M | $57,000 | $1.31M | $3.55M | $58,000 | -$3.17M |
| EBITDA | -$2.53M | -$8.67M | -$2.39M | $875,000 | $3.24M | $5.42M | $2.14M | -$734,000 |
| EPS (basic) | -0.03 | -0.07 | -0.02 | — | 0.01 | 0.03 | 0.00 | — |
| EPS (diluted) | -0.03 | -0.07 | -0.02 | — | 0.01 | 0.02 | 0.00 | — |
| Weighted avg. shares (diluted) | 140.36M | 140.26M | 140.06M | — | 150.38M | 148.57M | 143.34M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $7.79M | $9.87M | $12.14M | $17.05M | $10.40M | $6.92M | $5.03M | $6.20M |
| Receivables | $18.82M | $19.42M | $17.18M | $17.80M | $25.52M | $26.95M | $23.48M | $20.66M |
| Inventory | $32.50M | $33.29M | $31.88M | $30.26M | $40.71M | $40.13M | $38.81M | $38.63M |
| Current assets | $60.61M | $64.78M | $62.62M | $78.25M | $78.33M | $75.59M | $69.14M | $67.12M |
| PP&E, net | $5.45M | $5.54M | $5.85M | $6.20M | $10.01M | $10.45M | $10.73M | $10.13M |
| Goodwill | $6.07M | $6.07M | $6.07M | $6.07M | $7.30M | $7.30M | $7.30M | $7.30M |
| Intangibles | $229,000 | $252,000 | $275,000 | $299,000 | $7.06M | $7.49M | $7.92M | $8.36M |
| Total assets | $75.22M | $79.67M | $78.00M | $94.14M | $106.32M | $103.48M | $95.83M | $93.84M |
| Current liabilities | $30.27M | $29.96M | $18.77M | $29.48M | $35.50M | $30.60M | $29.58M | $28.58M |
| Short-term debt | $4.77M | $3.72M | $3.72M | $3.50M | — | — | — | — |
| Long-term debt | $5.44M | $7.29M | $8.10M | $11.03M | $17.40M | $22.28M | $22.17M | $22.04M |
| Total debt | $10.21M | $11.01M | $11.81M | $14.53M | $17.40M | $22.28M | $22.17M | $22.04M |
| Total liabilities | $37.96M | $39.65M | $29.40M | $43.19M | $55.94M | $54.98M | $51.96M | $50.87M |
| Shareholders' equity | $37.26M | $40.02M | $48.60M | $50.95M | $50.38M | $48.50M | $43.88M | $42.96M |
| Net debt | $2.41M | $1.14M | -$322,000 | -$2.53M | $7.00M | $15.36M | $17.14M | $15.84M |
| Shares outstanding | 140.45M | 140.26M | 140.07M | 140.04M | 140.00M | 139.32M | 139.08M | 139.05M |
| Cash flow statement | ||||||||
| Operating cash flow | -$855,000 | -$7.31M | -$2.11M | $5.38M | $4.61M | $1.28M | $1.28M | $665,000 |
| Capital expenditure | $389,000 | $247,000 | $194,000 | $395,000 | $430,000 | $366,000 | $1.19M | $672,000 |
| Free cash flow | -$1.24M | -$7.55M | -$2.31M | $4.99M | $4.18M | $910,000 | $87,000 | -$7,000 |
| Investing cash flow | -$362,000 | -$5.19M | $10.22M | $4.68M | $4.68M | -$317,000 | -$1.14M | -$567,000 |
| Financing cash flow | -$1.11M | $10.56M | -$13.28M | -$3.54M | -$5.77M | $662,000 | -$919,000 | -$854,000 |
| Depreciation & amortization | $500,000 | $500,000 | $534,000 | $1.82M | $700,000 | $800,000 | $1.07M | $1.15M |
| Stock-based compensation | $830,000 | $875,000 | $746,000 | $727,000 | $600,000 | $800,000 | $758,000 | $840,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.